Chinese biotech firm Rec-Biotechnology (RecBio) has secured over 1.5 billion yuan ($227.4 million) in its Series B round to fund the clinical trials of its product candidates including recombinant COVID vaccines.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
